Completed PHASE2 INTERVENTIONAL 2-arm NCT00886691

Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

A Phase II Randomized, Double-Blinded Evaluation of Oral Everolimus (RAD001) Plus Bevacizumab vs. Oral Placebo Plus Bevacizumab in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Sponsor: GOG Foundation

Conditions Recurrent Fallopian Tube Carcinoma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma

Interventions Bevacizumab Everolimus Laboratory Biomarker Analysis Placebo

Updated 10 times since 2017 Last updated: Jan 10, 2022 Started: Dec 27, 2010 Primary completion: Jun 27, 2014 Completion: Mar 23, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00886691, this PHASE2 trial focuses on Recurrent Fallopian Tube Carcinoma and Recurrent Ovarian Carcinoma and remains completed. Sponsored by GOG Foundation, it has been updated 10 times since 2010, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Mar 2022 — Jul 2024 [monthly]

Completed PHASE2

Status: Unknown Status → Completed
Feb 2021 — Mar 2022 [monthly]

Unknown Status PHASE2
Jan 2021 — Feb 2021 [monthly]

Unknown Status PHASE2

▶ Show 5 earlier versions

Apr 2020 — Jan 2021 [monthly]

Unknown Status PHASE2

Status: Active Not Recruiting → Unknown Status
Aug 2018 — Apr 2020 [monthly]

Active Not Recruiting PHASE2

Status: Unknown Status → Active Not Recruiting
Jun 2018 — Aug 2018 [monthly]

Unknown Status PHASE2
Feb 2017 — Jun 2018 [monthly]

Unknown Status PHASE2
Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE2

First recorded

Dec 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GOG Foundation
National Cancer Institute (NCI)

Data source: GOG Foundation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abington, United States , Ames, United States , Anderson, United States , Ann Arbor, United States , Aurora, United States , Burbank, United States , Camden, United States , Charlotte, United States , Chicago, United States , Cleveland, United States and 24 more locations